UNASSIGNED: Neoadjuvant chemotherapy (NACT) prior to liver resection is advantageous for @entity1 with @entity14 (CLM). Bevacizumab- or cetuximab-based NACT may affect @entity1 outcome and curative resection rate, but comparative studies on differential tumour regression grade (TRG) associated with distinct antibodies-associated regimens are lacking. Ninety-three consecutive @entity1 received NACT plus bevacizumab (n  =  46) or cetuximab (n  =  47) followed by CLM resection. Pathological response was determined in each resected @entity3 as TRG rated from 1 (complete) to 5 (no response). Except for @entity984 mutations prevailing in bevacizumab versus cetuximab (57 vs. 21  %, p  =  0.001), @entity1 characteristics were well balanced. Median follow-up was 31  months (IQR 17-48). Bevacizumab induced significantly better pathological response rates ( @entity17198 -3: 78 vs. 34  %, p  <  0.001) as well as complete responses ( @entity17198 : 13 vs. 0  %, p  =  0.012) with respect to cetuximab. Three-year progression-free survival (PFS) and @entity1349 ( @entity1349 ) were not significantly different in the two cohorts. At multivariable analysis, significant association with pathological response was found for number of resected metastases (p  =  0.015) and bevacizumab allocation (p  <  0.001), while @entity984 mutation showed only a trend. Significant association with poorer PFS and @entity1349 was found for low grades of pathological response (p  =  0.009 and p  <  0.001, respectively), R2 resection or presence of @entity6687 (both p  <  0.001) and presence of @entity984 mutation (p  =  0.007 and p  <  0.001, respectively). Bevacizumab-based regimens, although influenced by the number of metastases and @entity984 status, improve significantly pathological response if compared to cetuximab-based NACT. Possible differential impact among regimens on @entity1 outcome has still to be elucidated.

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity6687 :: ('MESH:D001651', 'Disease') :: ['extrahepatic disease'] @entity17198 :: ('7195', 'Gene') :: ['TRG1'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer liver metastases'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer liver metastases']
